|
Mar 13
|
Takeda’s $770M deal deepens Big Pharma’s omics push
|
|
Feb 24
|
The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)
|
|
Feb 17
|
TAK vs. DSNKY: Which Stock Is the Better Value Option?
|
|
Feb 15
|
Is Takeda Pharmaceutical Company Limited (TAK) the Best Japanese Stock to Buy in 2025?
|
|
Feb 12
|
BBI announces $31m facility for Shire to enhance asset finance
|
|
Feb 10
|
Are orexins the next golden child of neuroscience?
|
|
Jan 2
|
Japanese Stocks Are in the Spotlight Again. Hopes Are High for 2025.
|
|
Oct 3
|
Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?
|
|
Sep 30
|
Tempus Stock Up Following Collaboration Expansion in Oncology R&D
|
|
Sep 27
|
How Many Stocks Should You Own?
|
|
Sep 27
|
Tempus AI expands oncology collaboration with Takeda
|
|
Sep 18
|
Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries
|
|
Sep 17
|
TAK vs. STVN: Which Stock Is the Better Value Option?
|
|
Sep 17
|
Is Takeda Pharmaceutical Co. (TAK) a Great Value Stock Right Now?
|
|
Sep 16
|
Vatroslav Mateljic Appointed General Manager of Takeda Canada
|
|
Jun 26
|
Takeda Announces New Assignments of Directors
|
|
Jun 24
|
FDA Expands argenx's (ARGX) Vyvgart Label to Treat Rare Disorder
|
|
Jun 24
|
Takeda reports positive data from Phase IIb trial of ITP treatment
|
|
Jun 24
|
EC approves Takeda’s Fruzaqla for metastatic colorectal cancer
|
|
Jun 24
|
Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies
|